Hardy TS Kagimoto founded a biotech company after working at Kyushu University Hospital, where he developed an adjuvant to stain containing BBG250 (which had been invented by Kyushu University in Japan). The product was launched in Europe after a self-conducted Phase III study in India and the US, and is now established de-facto-standard status in ophthalmic surgery.
He then founded Healios K.K. in 2011 to realize his driving objective, the development of a therapy for age-related macular degeneration.
Masanori Sawada joined Healios K.K. in 2012, after working at the Department of Medicine in the Division of Respirology, Neurology, and Rheumatology at Kurume University Hospital.
His work helped to launch Kobe Research Institute, and he has contributed to establishing culturing methods for iPS cell–derived RPE cells at actual production levels.
He opened a collaborative research laboratory with Osaka University in 2014, and is now engaged in developing an automated cell culture system.
Yoshinari Matsuda founded his own law office after working for a large law firm.
He has served in leading roles for multiple tasks in the M&A and finance fields. Since becoming a director at Healios in 2013, he has contributed to obtaining funding and established the company’s administrative organization, including business collaborations.
Al Reaves has consistently delivered important results in the development of medical drugs in the ophthalmologic field.
His lifework has been focused on the development of drugs for age-related macular degeneration, and while at Novartis, led the clinical development program for Visudyne and began the X-US development of Lucentis®, which became a standard of treatment for age-related macular degeneration and other retinal indications.
He became a director at Healios in 2013 after working for Acucela Inc. as Senior Vice President.
Kouichi Tamura led all Transplantation research projects at Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.), and played a core role to develop Tacrolimus, a cornerstone Immunosuppressant. After the merger to become Astellas, he served as a Senior Vice President and Director of Astellas Research Institute of America, and developed the Drug Discovery Research on Immunology, Inflammatory and Central Nervous System.
He became a Corporate Officer and Head of the Kobe Research Institute at Healios in 2014.
Michihisa Nishiyama led the global development of tacrolimus (Prograf®), a standard immunosuppressant, to a successful conclusion at Fujisawa Pharmaceutical Co. Ltd. (currently Astellas Pharma Inc.) After launching tacrolimus, he created a marketing network across more than 70 countries, including the US and European countries.
He has experience in both global development/marketing and managing biotech ventures.
He became an outside director of Healios in 2014, then a director in charge of domestic development since 2016.
Michael Alfant is a former president of the American Chamber of Commerce in Japan and CEO of Fusion Systems Group.
With his abundant experience as an entrepreneur and manager of multinational enterprises, he has worked to build bridges between entrepreneurs in Japan and the US.
He became an outside director of Healios in 2013.
Hiromitsu Ogawa is the founder and chairperson of the board of CAI International, Inc. (NYSE: CAI), an intermodal freight container leasing and management company. He took the company public in May 2007. Prior to founding CAI, he worked in the pharmaceutical and beverage industries in sales promotion and marketing in Japan.
He makes a significant contribution to the stem cell industry by both serving on the global advisory council of the International Society for Stem Cell Research (ISSCR) since 2011 and also establishing the “Ogawa-Yamanaka Stem Cell Prize,” along with Dr. Shinya Yamanaka and Gladstone Institutes in 2015.
He became an outside director of Healios in 2016.
Go Nakano founded a company in his student days, and led an IPO for a venture company.
After serving as CFO at an IT-related listed company and working on disclosure practices and corporate governance, he worked for a sovereign wealth fund (Innovation Network Corporation of Japan).
He became a statutory auditor at Healios in 2014.
Senior partner of Lexwell Partners
Akimitsu Hirai is a leading figure in the field of conflict of interest for academia and industry in Japan. He concurrently serves as an outside director for biotech venture companies.
He became a statutory auditor for Healios in 2013.
After working for Deloitte Touche Tohmatsu LLC, Jun Narimatsu worked for the Department of Listing at the Tokyo Stock Exchange on the implementation of disclosure rules. He joined Cookpad Inc. and played a key role in the listing of the company after establishing a management system as CFO. While running his own company, he supports venture companies as an outside director.
He became a statutory auditor of Healios in 2014.